A PHASE I, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF ASCENDING DOSES OF AZD5363 UNDER ADAPTABLE DOSING SCHEDULES IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
- Registry ID
- D3610C00001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2016-05-10
- Completion date
- 2019-07-30
- Last update
- 2013-11-07
Conditions
Related clinical trials
- A FIRST-IN-HUMAN PHASE I, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER DOSE ESCALATION TRIAL OF BI 765049 AND BI 765049 + EZABENLIMAB ADMINISTERED BY REPEATED INTRAVENOUS INFUSIONS IN PATIENTS WITH MALIGNANT SOLID TUMORS EXPRESSING B7-H6
- AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202)
- A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES
- AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) -- CORE PROTOCOL
- A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABLITY AND PHARMACOKINETICS OF AB-16B5 IN SUBJECTS WITH AN ADVANCED SOLID MALIGNANCY.
- A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES
View on source registry